Acute Myeloid Leukemia: Ready for Prime Time? Expiration Date: 8/7/13 Androgen Deprivation Therapy: Minimizing Exposure and Mitigating Side Effects Expiration Date: 9/5/13 Use of Endobronchial Ultrasound and Endoscopic Ultrasound to Stage the
Search Results
JNCCN CE Offerings
Six (or More) Drugs in Search of a Mechanism: DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes
Steven D. Gore
of gene expression by 5-Aza-2′-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms . Leukemia 2005 ; 19 : 103 – 111 . 8
NCCN Task Force Report: Molecular Markers in Leukemias and Lymphomas
Jerald P. Radich, Andrew D. Zelenetz, Wing C. Chan, Carlo M. Croce, Myron S. Czuczman, Harry P. Erba, Sandra J. Horning, Jane Houldsworth, B. Douglas Smith, David S. Snyder, Hema M. Sundar, Meir Wetzler, and Jane N. Winter
; 112 : Abstract 1071 . 94 Mrozek K Marcucci G Paschka P . Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular
The Role of Flow Cytometry in Myelodysplastic Syndromes
Michael R. Loken and Denise A. Wells
S Safford M . Flow cytometric characterization of acute myeloid leukemia. Part 1: significance of light scattering properties . Leukemia 1991 ; 5 : 315 – 321 . 9. Hurwitz CA Loken MR Graham ML . Asynchronous antigen expression in B
Impact of Age and Comorbidity in Myelodysplastic Syndromes
Reinhard Stauder, Thomas Nösslinger, Michael Pfeilstöcker, Wolfgang R. Sperr, Friedrich Wimazal, Otto Krieger, and Peter Valent
and acute myeloid leukemia in Tyrol: incidence and distribution [abstract] . Onkologie 2003 ; 23 ( Suppl 5 ): S121 . Abstract P683 . 11. Germing U Strupp C Kundgen A . No increase in age-specific incidence of myelodysplastic syndromes
HSR24-159: Relationship Between Durable Transfusion Independence (TI) and Survival Outcomes in Patients (Pts) With Lower-Risk Myelodysplastic Syndrome (LR-MDS): An Analysis From US Health Insurance Claims Data
Rami S. Komrokji, Nishan Sengupta, Dylan Supina, Shyamala Navada, Ravi Potluri, Rohit Tyagi, Timothy Werwath, Zhouer Xie, Eric Padron, and David Sallman
.1, D46.9, D46.A, and D46.B) from Oct 2015 to Mar 2023. No diagnosis of MDS/acute myeloid leukemia (AML) or use of higher-risk MDS or AML medication before their respective index diagnosis dates were allowed. Lines of treatment were determined by the
CLO24-084: Myeloid Sarcoma in a Patient With Marfan Syndrome
Nitya Batra, Atulya Aman Khosla, Shyam Poudel, and Daniel Ezekwudo
myeloid leukemia (AML), however, it can occur solitarily or coexist with myelodisplastic syndrome (MDS) and other myeloproliferative neoplasms. Most common isolated sites are skin, bone, soft tissues and lymph nodes. We present a rare gastrointestinal
QIM23-131: A Retrospective Review of Myelodysplastic Syndrome Management (MDS) at Watson Clinic LLP: From Diagnosis to Primary Course of Treatment
Shane Burke, Galina Vugman, Noreen McGowan, and Michelle Sharrett
Comprehensive Cancer Network (NCCN) Guidelines recommend treatment patterns based on risk of progression into Acute Myeloid Leukemia (AML). Adherence to these guidelines improves survival rates in patients with MDS. An MDS work-up should include an extensive
CGE23-071: Real World Data on the Implementation of a Hereditary Hematological Myeloid Malignancy Workflow: Experience of a Single Academic Medical Center
Moon Ley Tung, Athena Puski, Jennifer L Stinson, Nicole Huser, and Madeline VanDerGraaf
Background: Hereditary myeloid malignancy syndromes (HMMS) are increasingly recognized in adult patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Timely diagnosis of HMMS is critical to ensure appropriate bone marrow
QIM23-137: Improving Hematology-Oncology Education in Internal Medicine Residency—A Single Institution Quality Improvement Project
Georgio Medawar, Jessica Khoury, Antoine Salloum, and John Miskovsky
prior and after a 5-lecture series. The topics covered were acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), lung cancer, colon cancer, and breast cancer. The lectures were prepared based on National Comprehensive Cancer Center (NCCN
